Clinical trial Intelligence for contract research organizations
We help CROs win business and enhance drug development services. Make better-informed decisions while bidding on and implementing clinical trials.
There are some trials that could be great for your business and others that might not be. But without high-quality intelligence, it can be hard to assess or maximize a trial’s potential.
How we help
Our thorough and extensive clinical trial intelligence for CROs will help your organization:
We’ll help you identify companies active in your territory and their phases of development. Spot where to run trials, with our data on where comparator trials have been approved and the availability of regional investigators.
You can size up competing trials, because we monitor and benchmark them, prioritizing investigators and tracking enrollment. And to help you mitigate risks, we can provide intelligence on safety issues faced by trials of similar designs.
24 Oct 2019
Patient-centric trials have been growing for years. Backed by data from Citeline’s Trialtrove, our latest infographic reveals the trends, the sponsors, and the impact on outcomes around Phase I, II, and III industry-sponsored, patient-centric trials.
11 Oct 2019
A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.
11 Oct 2019
See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.
26 Sep 2019
To increase flexibility and efficiency in drug development, master protocols have emerged as an innovative clinical trial design, including basket and umbrella trials. Learn more about how these approaches are being used within oncology research through an overview of the clinical landscape, trial outcomes and trends.
Citeline, Pink Sheet
26 Sep 2019
Rising costs, patient recruitment issues, shifting regulations, and more are making bringing new drugs to market more difficult than ever. Explore changes in clinical trial design being adopted in response to these challenges with reporting from Pink Sheet.
By Jonathan Slater 02 Sep 2019
The Generating Antibiotic Incentives Now (GAIN) Act passed into law on July 9, 2012. Seven years on, we review the drugs that have obtained QIDP status, the companies involved, and the clinical trial landscape.
12 Aug 2019
Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.
06 Aug 2019
The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.
30 Jul 2019
KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.
03 Jul 2019
With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain.
02 Jul 2019
For a snapshot of the new active substances (NAS) successfully launched last year, download the data-packed New Active Substances (NAS) Launched During 2018 infographic from Citeline.
02 Jul 2019
The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).
Citeline, Sitetrove, Trialtrove, Pharmaprojects
02 Jul 2019
Citeline is the industry’s most comprehensive, reliable and up-to-date global clinical trial intelligence suite, designed to help you save time and money by enrolling patients faster. Our team of more than 250 industry experts transform data into knowledge, integrating robust drug, trial, investigator, and site intelligence.
By Christine Blazynski, PhD 25 Jun 2019
The average cost of bringing a new drug to market continues to rise, with varying levels of investments across the highly competitive biopharmaceutical industry. To assess the potential effect of varying investments on trial activity and operations, this article reviews trial benchmarks within the active oncology therapeutic area. Industry-sponsored clinical trials across all oncology indications covered by Informa Pharma Intelligence’s Trialtrove were assessed, comparing metrics by company size based on pharma sales, and the identical benchmarks for breast cancer and rare cancers were also analyzed.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: